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Acquired generalized lipodystrophy (AGL) is a rare condition characterized by an altered
distribution of adipose tissue and predisposition to develop hepatic steatosis and fibrosis,
diabetes, and hypertriglyceridemia. Diagnosis of AGL is based on the observation
of generalized fat loss, autoimmunity and lack of family history of lipodystrophy. The
pathogenic mechanism of fat destruction remains unknown but evidences suggest an
autoimmune origin. Anti-adipocyte antibodies have been previously reported in patients
with AGL, although their involvement in the pathogenesis has been poorly studied and the
autoantibody target/s remain/s to be identified. Using a combination of immunochemical
and cellular studies, we investigated the presence of anti-adipocyte autoantibodies
in patients with AGL, acquired partial lipodystrophy, localized lipoatrophy due to
intradermic insulin injections or systemic lupus erythematosus. Moreover, the impact
of anti-adipocyte autoantibodies from AGL patients was assessed in cultured mouse
preadipocytes. Following this approach, we identified anti-perilipin 1 IgG autoantibodies
in the serum of patients with autoimmune variety-AGL, but in no other lipodystrophies
tested. These autoantibodies altered the ability of perilipin 1 to regulate lipolysis in
cultured preadipocytes causing abnormal, significantly elevated basal lipolysis. Our data
provide strong support for the conclusion that perilipin 1 autoantibodies are a cause of
generalized lipodystrophy in these patients.
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INTRODUCTION
Acquired generalized lipodystrophy (AGL), or Lawrence syndrome (ORPHA:79086), is a rare
disease that usually develops during childhood and adolescence. It is characterized by a selective
loss of adipose tissue from large areas of the body, particularly the face, arms, and legs (1).
Reported in more than 100 cases with a male-to-female ratio of 1:3, most patients with AGL
have fasting and/or postprandial hyperinsulinemia, severe hepatic steatosis, diabetes mellitus,
hypertriglyceridemia, and low serum levels of high-density lipoprotein cholesterol, leptin, and
adiponectin (1, 2). Approximately 25% of patients debut with an episode of panniculitis. Another
25% of cases present associated autoimmune diseases, particularly juvenile dermatomyositis. In
the remaining patients, the underlying mechanism of fat loss is not clear (idiopathic variety).
The metabolic complications are typically less severe in patients with the panniculitis-associated
phenotype compared with the other two subtypes (3).
Corvillo et al. Autoantibodies in Patients With AGL
The pathogenesis of AGL can vary, and the precise
mechanisms accounting for fat loss remain unknown. In patients
with the panniculitis and autoimmune varieties, loss of adipose
tissue is presumed to be due to either a cell-mediated or an
antibody-mediated autoimmune process or both (1). The only
evidence of anti-adipocyte autoantibodies was reported in a 33-
year-old male patient with AGL, insulin-resistant diabetes, and
acanthosis nigricans (4). The authors demonstrated IgG deposits
around the adipocytes using direct immunofluorescence on the
patient’s subcutaneous biopsy. However, the target autoantigen/s
have not been yet identified. In addition, some patients have been
reported to have chronic hepatitis with autoimmune features
and low complement C4 levels, suggesting involvement of
the complement classical pathway in the pathogenesis of fat
loss (5, 6). Unlike in AGL, scientific evidences exist for the
involvement of complement-dependent cytotoxicity in the lysis
of adipocytes in patients with acquired partial lipodystrophy
(APL) (7). A recent work presented three males diagnosed
of generalized lipodystrophy, with subsequent development of
pilocytic astrocytoma (8). All of them gained body fat or weight
after surgical removal of the tumor and/or chemotherapy. The
authors hypothesized that the tumor secreted anti-adipocyte
antibodies, which could have induced adipocyte lysis.
Here, we demonstrate the presence of anti-adipocyte
antibodies predominantly directed against perilipin 1 (PLIN1)
in patients with AGL. PLIN1 is the most abundant adipocyte-
specific protein that coats lipid droplets, which is required
for optimal lipid incorporation and release from the droplet.
Mutations in the gene encoding PLIN1 have been described
in a group of patients with familial partial lipodystrophy
type 4 (FPLD4) (9, 10). Moreover, we show that anti-PLIN1
autoantibodies, but not IgG from healthy donors, significantly
increased basal lipolysis in cultured preadipocytes. These
findings reveal a novel autoimmune mechanism accounting for
the loss of adipose tissue in patients with AGL.
MATERIALS AND METHODS
Patients
Five patients (4 F/1M) were diagnosed with AGL on the basis
of fat loss during childhood or adulthood affecting large areas
of the body, and having ruled out other causes of weight loss.
Congenital generalized lipodystrophy was also excluded based on
the natural course of the disease, clinical features, age at onset,
and discarding pathogenic variants in both the CGL-related
genes AGPAT2, BSCL2, CAV1, and PTRF, and also FPL-related
genes LMNA and PPARG. No consanguinity was reported in any
case. We used the criteria for designating AGL variety described
by Misra and Garg (3): I) Autoimmune variety: AGL follows
an autoimmune diseases or the presence of autoantibodies; II)
Panniculitis variety: Tender subcutaneous nodules that herald the
Abbreviations: AGL, acquired generalized lipodystrophy; APL, acquired partial
lipodystrophy; ATGL, adipose triacylglycerol lipase; CGI-58, comparative
gene identification-58; FPLD4, familial partial lipodystrophy type 4; hMSCs,
human mesenchymal stem cells; HSL, hormone-sensitive lipase; IBMX,
isobutylmethylxanthine; I-LA, localized lipoatrophy due to intradermic insulin
injections; PLIN, perilipin; SLE, systemic lupus erythematous.
onset of AGL; III) Idiopathic variety: No history of autoimmune
disease or panniculitis. Physical, anthropometric, and clinical
features from patients with AGL are shown in Table 1.
Biological Samples
We collected serum and plasma samples from five patients
with AGL. As disease control, we used serum from 8 patients
diagnosed with acquired partial lipodystrophy (APL), according
to the criteria by Araujo-Vilar and Santini (11). Additionally, we
tested serum from 11 patients with localized lipoatrophy due to
intradermic insulin injections (I-LA), 10 patients with systemic
lupus erythematous (SLE), and 20 healthy volunteers. Serum and
EDTA plasma samples were obtained under standard conditions
upon informed consent from the donors; blood was collected in
plain tubes, allowed to clot at room temperature, and centrifuged
for 10min at 4◦C. Serum and plasma were then aliquoted and
stored frozen at−80◦C until their use.
Adipose tissue from four female donor patients (ages 22 to
53, mean 40 years of age, and BMI range 42.60 to 19.57, mean
31.3) undergoing elective liposuction was obtained for isolation
of hMSCs. Patients were otherwise healthy and received no
drug therapy. Active infection by HIV, hepatitis C virus, and
syphilis was ruled out by serological analyses. For histological
and western blot analyses, the subcutaneous adipose tissue was
biopsied. The tissues were frozen and included in optimal cutting
temperature compound for histological studies. Adipose tissue
was lysed to extract total protein and kept frozen at −80◦C until
used.
All procedures involving human participants were performed
in accordance with the standards of the Ethics Review Panel of
La Paz University Hospital (Madrid, Spain) and with the 2013
Helsinki declaration and its later amendments or comparable
ethical standards. All participants provided written informed
consent for participation in the study and for the publication of
their clinical and biochemical information.
Protein Extraction From Adipose Tissue
Total protein extraction from subcutaneous white adipose tissue
was performed using Protein extraction kit (101bio) following
manufacturer’s instructions. The extracts were depleted of
albumin and IgG with ProteoPrep R© Immunoaffinity Albumin
& IgG Depletion Kit from Sigma. Subsequently, protein
concentration was determined using Bradford assay and the
samples were stored at−80◦C until used.
Western Blotting
Ten micrograms of adipose tissue extract were run on precast
4–20% Tris-HCl Ready Gels (Bio-Rad Laboratories) in the
presence of Tris-glycine-SDS running buffer. Proteins were
transferred to a polyvinylidene fluoride membrane using the
iBlot R© 7-Min Blotting System (Thermo Fisher), following the
manufacturers indications. Membranes were blocked for 1 h at
room temperature in assay buffer containing 10mM Tris-HCl,
pH 7.6, 5% of fetal calf serum, 150mMNaCl and 1% of Tween-20.
All incubations with human serum were performed for
overnight at 4◦C at a 1:100 dilution in assay buffer. The
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TABLE 1 | Clinical features of patients with AGL.
Variable AGL1 AGL2 AGL3 AGL4 AGL5 Reference range
Sex Female Male Female Female Female
Age (years) 33 10 13 51 33
Lipodystrophy onset (years) 5 2 3 5 31
AGL subtype Autoimmune Autoimmune Autoimmune Idiopathic Idiopathic
BMI (kg/m2) 17.3 15* 16U 19.2 15.2 18–25
% total fat£ 8 NA 11 20.5 10.2 27.2–33.3
Acanthosis Yes No Yes No No
Glucose (mg/dL) 121 104 98 92 81 60–110
Insulin (µU/mL) Insulin-treated 26 275.9 114 3.7 2.6–24.9
Diabetes Yes No No No No
HbA1c (%) 6.8 5.3 5.8 5.4 5.4 4.0–5.5
Hypoleptinemia Yes Yes Yes Yes Yes
Triglycerides (mg/dL) 79 104 718 138 69 25–115
Fatty liver
†
No No Yes No No
ALT (UI/L) 50.6 55.8 131 27 26 5–31
AST (UI/L) 34.6 35.4 77 18 20 5–32
Autoimmunity T1DM Anti-GAD
Anti-TPO
APCA No No
Immunosuppressant treatment No No No No No
IgG (mg/dL) 1,280 1,120 1,415 988 1,270 725–1,900
IgA (mg/dL) 135 139 196 122 230 50–340
IgM (mg/dL) 97.2 92.2 193 94 86.4 45–280
C3 (mg/dL) 112 109 170 143 97.1 75–135
C4 (mg/dL) 17.1 24.2 35 33.9 16.8 14–60
BMI, body mass index; ALT, Alanine aminotransferase; AST, Aspartate aminotransferase; T1DM, type 1 diabetes mellitus; Anti-GAD, anti-glutamic acid decarboxylase antibody; APCA,
anti-parietal cell antibodies; Anti-TPO, anti-Thyroperoxidase antibody; NA, not available.
* BMI among 13.7-18.5 is considered normal for 10 years old children.
U BMI among 14.9-20.8 is considered normal for 13 years old children.
£ Percentage of total fat was measured using dual-energy x-ray absorptiometry.
†
Liver steatosis was assessed by means of ultrasonography.
membranes were washed three times with 0.1% of Tween-
20-containing TBS buffer. Negative samples for anti-adipocyte
antibodies were also tested at 1:100 and 1:50 dilutions but
remained negative. The washed membranes were incubated with
alkaline phosphatase-conjugated anti-human IgG (1:8,000; 1 h
at room temperature) from Jackson Immunoresearch diluted
in assay buffer. To detect PLIN1 in adipose tissue extracts,
the membranes were incubated with an Antigen Affinity-
purified sheep polyclonal anti-PLIN1 antibody directed to
the peptide spanning Thr8-Ala145 (catalog. #AF6615, from
R&D) at 1µg/mL. Additionally, a rabbit polyclonal anti-PLIN1
antibody targeting amino acids surrounding Asp418 (named
D418 for us, catalog. #3470, from Cell Signaling Technology)
was used to compare autoantibody reactivity against the C-
terminal domain of PLIN1. In both experiments appropriate
alkaline phosphatase-conjugated antibodies (Sigma) were used
and the blots were developed with 5-bromo-4-chloro-3-indolyl-
phosphate/nitro blue tetrazolium (BCIP/NBT, from VWR).
To demonstrate the specificity of the autoantibodies in
patients with AGL, serum samples were preabsorbed at 1:100
dilutions with 14 µg of recombinant PLIN1 (OriGene, transcript
variant 1, RefSeq: NP_002657) overnight at 4◦C. As control
sample, an identical volume of PBS was mixed with the patient’s
serum. After the blockage step, tissue extracts were blotted with
either treated or non-treated patient’s serum as described above.
Immunohistological Studies
Cryosections of normal human subcutaneous adipose tissue
obtained from healthy donors were fixed for 10min in acetone
and blocked with 10% bovine serum albumin. We used serum
as the primary antibody at a 1:10 dilution, followed by a
fluorescein isothiocyanate-conjugated rabbit anti-human IgG
(1.5µg/mL, F0315, from Dako) to detect immunoglobulin
deposition. Immunofluorescence images were obtained with
an Olympus camera (Olympus Corporation) mounted on an
Olympus microscope and analyzed with DP software (Olympus).
Human Mesenchymal Stem Cells Isolation
Isolation of hMSC was performed as described by Fuentes-Julián
et al. (12). Briefly, liposuction-derived adipose tissue was washed
with PBS and digested with 0.09% collagenase I in PBS (Gibco)
for 45min at 37◦C under gentle agitation. The reaction was
stopped with FBS (Gibco) and centrifuged at 300 g for 10min
to separate the stroma vascular fraction of adipose tissue of the
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pelleted cells from the floating adipocytes. Pellets were treated
with erythrocyte lysis buffer (160mM NH4Cl; 10mM KHCO3;
1mM EDTA; all from Sigma) for 15min at room temperature,
the erythrocytes-free cell fraction was washed with PBS and
seeded at a 1 × 106 cells per plate density on 10-cm plates
(Costar R©, Corning) in standard DMEM (Gibco), supplemented
with 10% FBS and 1% penicillin-streptomycin (Sigma).
In vitro Adipogenesis
Human MSCs obtained from adipose tissue were differentiated
into preadipocytes in an adipogenic culture medium
containing: DMEM supplemented with 10% FBS, 1% penicillin-
streptomycin, 500µM isobutylmethylxanthine (IBMX), 1µM
dexamethasone, 1µM indomethacin and 10µg/mL of insulin
(Lilly). The medium was refreshed every 48 h. Three weeks after
differentiation, adipogenesis was completed as judged by the
enrichment in big-sized lipid droplets.
3T3-L1 cell line was differentiated into preadipocytes for 2
weeks. Cells were cultured in DMEM medium supplemented
with 10% FBS, 1% penicillin-streptomycin, 500µM IBMX,
1µM dexamethasone and 10µg/mL of insulin. After 48 h
of culture, medium was replaced for DMEM medium
supplemented with 10% FBS, 1% penicillin-streptomycin
and 10µg/mL of insulin for another 48 h. Differentiation
was subsequently completed by incubation in 10% FBS, 1%
penicillin-streptomycin-supplemented DMEM for 10 days.
Immunocytochemistry
Fixed (4% paraformaldehyde) cultured preadipocytes were
washed with PBS, blocked and permeabilized with 0.3% Triton
X-100 (Sigma) and 1% BSA-supplemented PBS. Cells were
overnight incubated at 4◦C with serum at 1:200 dilutions in a
0.3% Triton X-100 and 0.5% BSA-containing PBS buffer. After
three washing steps with PBS, the cells were incubated with
a FITC-conjugated polyclonal rabbit F(ab′)2 anti-human IgG
(Dako) (1:250) for 1 h at room temperature. To detect PLIN1,
cell cultures were incubated overnight at 4◦C with a rabbit
anti-human PLIN1 antibody (catalog number #3470, from
Cell Signaling Technology) at 1:100, and a convenient biotin-
conjugated secondary antibody (1:1000, Vector Laboratories).
The reaction was developed using avidin-Texas Red conjugated
(1:1000, A-2006, from Vector Laboratories). Plates were
then mounted with DAPI-containing Vectashield (Vector
Laboratories). To evaluate if AGL patients’ sera recognize
murine PLIN1, 3T3-L1-derived preadipocytes were processed as
described above for cultured human preadipocytes.
Strategy to Identify the Antigen
To determine the identity of the antigen targeted by the
autoantibodies in patients with AGL, a comprehensive review
of the literature (13, 14) and open-access databases (Courtesy
of Human Protein Atlas, www.proteinatlas.org) (15, 16) was
performed. Selected lipid droplet-associated proteins are
summarized in Table 2. The selection criteria used to prioritize
the antigen candidates were (a) similar molecular weight; (b)
major expression in white adipose tissue and (c) previous
associations with other lipodystrophy diseases.
Anti-PLIN1 Autoantibody Detection by
Enzyme-Linked Immunosorbent Assay
(ELISA)
ELISA microtiter plates (Medisorb, Nunc, VWR) were coated
with 100 ng/well of recombinant PLIN1 (OriGene) in carbonate-
bicarbonate buffer pH 9.6 (overnight, 4◦C). Plates were blocked
with PBS supplemented with 0.05% Tween-20 and 3% non-
fat milk and washed with PBS-Tween 0.1%. All samples were
added at 1:100 dilutions in assay buffer (1 h at 37◦C) and
run in duplicates. Upon washing, anti-PLIN1 autoantibodies
were detected using a peroxidase-conjugated anti-human IgG
at 1:10,000 (Jackson Immunoresearch). Color was developed
using (2,2′-Azinobis [3-ethylbenzothiazoline-6-sulfonic acid]-
diammonium salt (ABTS, from VWR) and absorbance was
measured at 405 nm.
Measurement of Lipolytic Activity
Mouse 3T3-L1 preadipocytes were cultured in 10% FBS, 1%
penicillin-streptomycin-containing DMEM supplemented with
0.0005 µCi/µl of palmitic acid-[9,10-3H (N)] (PerkinElmer),
overnight at 37◦C and 5% CO2. The next day, cells were washed
three times with PBS to remove the excess of isotope.
Plasma IgGwas purified by affinity chromatography in protein
G columns (ABT). In order to assess the effect of anti-PLIN1
autoantibodies on the lipolytic pathway, IgG purified from either
AGL patients or healthy donors was used. For the measurement
of basal lipolysis, preadipocytes were cultured in MEM medium
(Fisher Scientific) containing 1% penicillin-streptomycin, 2%
fatty acid-free BSA (Sigma). A 10µM isoprenaline solution
(Sigma) was added to this medium for the valoration of
stimulated lipolysis. Additionally, 300 µg of IgG purified from
either patients with autoantibodies or healthy donors were added
to the medium. Conditioned medium was collected at 60-,
120-, and 180-min time points and analyzed for radiolabeled
palmitic acid release in a liquid scintillation analyzer (Model
Tri-Carb R© 2800TR; PerkinElmer) after addition of Opti-Fluor
O (PerkinElmer). Additionally, other experiments were carried
out at 180 as the final time point, using 10 µg of human PLIN1
Antigen Affinity-purified Polyclonal Antibody (#AF6615, from
R&D) as a positive control.
Statistical Analyses
Statistical calculations were performed with Prism version 6.01
(GraphPad Software). Bonferroni’s multiple comparison test was
used for comparisons of all the groups. A P< 0.05 was considered
statistically significant in all analyses.
RESULTS
Serum From Patients With AGL Shows
Reactivity Against Adipocyte Lipid Droplets
Normal adipose tissue extracts were evaluated by western blot
by using AGL sera for the detection of transferred proteins. A
complex band pattern was observed (three bands at 60, 55, and 37
kDa) in samples from three patients with the autoimmune variety
of the disease (designated AGL1, AGL2, and AGL3, Table 1)
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TABLE 2 | Candidate antigens in acquired generalized lipodystrophy.
Gene Gene description RNA expression (TPM) Molecular weight (kDa) Subcellular location Pathology (MIM number)
FABP4 Fatty acid binding protein 4 3642.8 14.7 Cytoplasm/Nucleus –
PLIN1 Perilipin 1 1011.2 56.0 Lipid droplet Familial partial lipodystrophy type
4 (# 613877)
ADIPOQ Adiponectin 935.8 26.4 Secreted Adiponectin deficiency
(#612556)
LIPE Lipase E, hormone sensitive
type
868.9 116.6 Cytoplasm Familial partial lipodystrophy type
6 (# 615980)
PLIN4 Perilipin 4 810.9 136.0 Lipid droplet –
CIDEC Cell death-inducing DFA-like
effector c
760.1 26.8 Lipid droplet Familial partial lipodystrophy type
5 (#615238)
PNPLA2 Patatin-like phospholipase
domain-containing protein 2
419.8 55.3 Lipid droplet Neutral lipid storage disease with
myopathy (#610717)
CFD Factor D (adipsin) 378.7 27.0 Secreted Factor D deficiency (#613912)
LEP Leptin 321.7 18.6 Secreted Morbid obesity due to leptin
deficiency (#614962)
CIDEA Cell death-inducing DFA-like
effector a
220.9 24.7 Lipid droplet –
ACACB Acetyl-CoA carboxylase
beta
194.0 276.5 Mitochondria –
GYG2 Glycogenin 2 161.7 55.2 Cytoplasm/Nucleus
TUSC5 Tumor suppressor
candidate 5
109,9 19.3 Plasma membrane –
LGALS12 Lectin, galactoside-binding,
soluble 12
89.7 37.5 Mitochondria/Nucleus –
ACVR1C Activin A receptor type 1C 33.9 54.9 Plasma membrane –
TPM, transcripts per million; MIM, mendelian inheritance in man.
under reducing and nonreducing conditions (Figure 1A). In
contrast, no reactivity was observed in sera from 20 healthy
donors, 8 patients with APL and 11 patients with I-LA. The two
negative AGL cases in the series (AGL4 and AGL5) were retested
at 1:50 serum dilutions, but remained negative. Furthermore,
western blot assays were also developed using adipose tissue
extracts from different healthy donors obtaining identical results
(Figure S1).
Additionally, we used frozen sections of normal adipose tissue
to assess serum IgG binding to adipocytes. The results of indirect
immunofluorescence confirmed that IgG from those patients
with AGL presenting the autoimmune variety of the disease
(AGL1, AGL2, and AGL3), but not that from AGL patients
with the idiopathic variety (AGL4 and AGL5), reacted against
adipocytes (Figure 1B and Table 1). Considering that mature
white adipocytes store triglycerides within a large, single lipid
droplet, which occupies up to 90% of the cell volume, the precise
site of IgG reactivity (i.e., plasmatic membrane or lipid droplet
membrane) could not be determined in this experimental setting.
In order to establish the subcellular location and specific
antigen/s bound by autoreactive IgG in these patients, adipose
tissue-derived human mesenchymal stem cells (hMSCs) were
differentiated into preadipocytes (Figures 2A,B). After 3 weeks
of adipogenic induction, most cells presented intracellular lipid
vacuoles strongly bound by IgG from patients with AGL
(Figure 2C), thus demonstrating that the target autoantigen is a
lipid droplet component.
PLIN1 Is Targeted by Autoantibodies in
Patients With AGL
The search for hypothetical autoantigen candidates was
performed in silico as described in the Methods section and the
main candidates are shown in Table 2. Based on its significant
expression on the lipid droplet, compatible molecular weight and
pathological significance, the first interrogated candidate was
PLIN1. PLIN1 is one of the most abundant proteins on the lipid
droplet surface of mature white adipocytes (17), has a molecular
weight of 55.9 kDa, and heterozygous PLIN1 mutations are
associated with FPLD4 (9, 10).
Western blot assays with commercial polyclonal anti-PLIN1
antibody (#AF6615) performed on adipose tissue lysates yielded
a band pattern identical to that obtained with serum from
patients with AGL (Figure 3A). In addition, we performed an
ELISA assay to detect anti-PLIN1 specific antibodies in the serum
of patients with AGL, I-LA, APL, SLE and healthy donors,
using recombinant human PLIN1 as a target antigen. Only
AGL1, AGL2, and AGL3 (all of them with previous positive
results in western blotting) had detectable anti-PLIN1 IgG
autoantibodies (Figure 3B). Anti-PLIN1 autoantibodies were
found to be predominantly IgG1, although smaller amounts of
other subclasses were also detected (Figure 3C).
The perilipins (PLINs) comprise an ancient protein family
defined by N-terminal sequence homology (17). Although PLIN1
was the foremost autoantigen candidate, other perilipins, such
as PLIN2, PLIN3, and PLIN5, show high sequence homology
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FIGURE 1 | Screening for autoantibodies against adipose tissue in serum samples obtained from patients with acquired lipodystrophies. (A) Results of a western blot
screening performed on human adipose tissue extracts, under reducing (2BME +) or non-reducing (2BME –) conditions, incubated with serum samples from five
patients with acquired generalized lipodystrophy (AGL1 through AGL5), one patient with localized lipoatrophy due to intradermic insulin injections (I-LA), one patient
with acquired partial lipodystrophy (APL) and one healthy donor (NHS). (B) Indirect immunofluorescence of cryosections of human white adipose tissue with serum
from one NHS (left) and serum from one patient with AGL (right), incubated at 1:10 dilutions. IgG deposition on adipocytes (green) was detected with AGL sera as a
source of autoreactive immunoglobulins. Scale bars correspond to 100µm.
with PLIN1. To demonstrate autoantibody specificity for PLIN1,
we blocked AGL2 serum anti-PLIN1 IgG by preincubation with
an excess of recombinant human PLIN1. Upon blockade, a
significant reduction in the western blot signals (as compared
with untreated samples) was observed (Figure 3D). In support
of these data, confocal analyses demonstrated that IgG from
patients AGL1, AGL2 and AGL3 colocalizes with PLIN1 on
the lipid droplet. In contrast, no PLIN1/IgG colocalization was
detected with IgG from healthy donors and patients with SLE,
I-LA, or APL (Figure 4 and Figure S2).
In order to study the target domain of PLIN1 recognized
by the anti-PLIN1 autoantibodies, we performed a western
blot assay using a different polyclonal anti-PLIN1 antibody
specifically binding to the C-terminal domain (D418). This
antibody detected the 60 and 55 kDa, but no the 37 kDa
bands, in contrast with the reactivity obtained using the serum
from AGL1 and the polyclonal anti-PLIN1 antibody (#AF6615)
(Figure 5).
Anti-PLIN1 Autoantibodies Increase Basal
Lipolysis in Cultured Adipocytes
We hypothesized that the presence of anti-PLIN1 autoantibodies
in patients with AGL could contribute to the phenotype of
fat mass loss due to functional hindrance of perilipin. To
explore this possibility, we assessed the effect of purified IgG
from patients with AGL on the lipolytic activity of murine
adipocytes. In this experimental setting, the 3T3-L1 cell line
was chosen instead of hMSCs due to their higher differentiation
rate. First, by means of indirect immunofluorescence, we
verified that serum from patients with AGL recognized
mouse PLIN1 in mice adipose tissue extracts (Figure 6A) and
differentiated preadipocytes (Figure 6B). Subsequently, the basal
and isoproterenol-stimulated lipolysis of cultured preadipocytes
was measured by detecting the radiolabeled palmitic acid release
to the medium. Cultured adipocytes were treated with 300 µg of
purified IgG and lipolysis was measured at 60, 120, and 180min
thereafter. Cells treated with IgG from patient AGL3 showed
a significant increase in [3H]palmitic acid release under basal,
but not stimulated, conditions at all experimental times (P<0.01
at 2 h; P < 0.001 at 1 and 3 h) compared with cells treated
with healthy donor IgG (Figure 7A). In another experimental
setting measuring end-point release of [3H]palmitic acid after
3 h in basal conditions, a commercial anti-PLIN1 polyclonal
antibody (#AF6615) was used as positive control to block
lipolysis regulation. In these conditions, cells treated with
IgG from the remaining AGL patients (AGL1 and AGL2)
exhibited a significant increase of basal lipolysis (P < 0.01),
comparable to that induced by a polyclonal anti-PLIN1 antibody
(Figure 7B).
Clinical Features Associated With
Anti-PLIN1 Autoantibodies
We examined the clinical characteristics of five patients with
AGL, one male and four females (Table 1). In this cohort,
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FIGURE 2 | Autoantibody binding to cultured preadipocytes (A) Images of phase contrast microscopic picture of cultured hMSCs from healthy donors subjected to
adipocyte differentiation for 3 weeks. (B) Oil Red O-stained cell culture dishes were photographied using a digital camera. Preadipocyte monolayers images were
obtained with an inverted-phase contrast microscope at a magnification of 200x. (C) Results of confocal microscopic analysis of human preadipocyte cell cultures.
Serum IgG from patients with AGL reacts with an antigen localized at the lipid droplet membrane. Scale bars correspond to 18µm. DNA was stained with
4′,6-diamidino-2-phenylindole (DAPI, blue). IgG binding was detected using FITC-conjugated rabbit anti-human IgG (green).
three individuals presented the autoimmune variety of the
disease while the remaining cases were classified as idiopathic.
The lipodystrophy onset happened during childhood except for
AGL5 in whom lipodystrophy appeared after withdrawal of
oral contraceptives at the age of 31. Anti-PLIN1 autoantibodies
were detected in the patients with the autoimmune variety of
the disease (AGL1, AGL2, and AGL3). AGL1 developed type
1 diabetes mellitus during childhood, and at the moment of
this study she had just started insulin treatment. Moreover,
despite an increase of transaminases (ALT and AST) levels,
she has not yet been diagnosed with fatty liver disease. AGL2
presented an elevation of transaminases and clinical signs of
insulin resistance (hyperinsulinemia and the detection of anti-
glutamic acid decarboxylase antibody), although he has not
developed diabetes so far. AGL3 suffered severe metabolic
disturbances like hyperinsulinemia and hepatic steatosis with a
marked elevation of circulating triglycerides and transaminases
(ALT and AST).
DISCUSSION
This study provides the first evidence for the presence of
autoantibodies against the lipid droplet protein PLIN1 in patients
with AGL. To date, the only description of antibodies against
adipose tissue in human lipodystrophies was presented by
Hübbler et al. (4). In that work, the authors established that IgG
from one patient with AGL was able to react with adipocytes as
judged by indirect immunofluorescence. Although the staining
pattern provided by Hübler and colleagues was similar to that
obtained by us (Figure 1B), they assumed, without further
evidence, that antibody binding occurred on the plasmatic
membrane instead of the lipid droplet membrane.
PLINs are an ancient family of proteins evolutionarily
conserved from insects tomammals (18).While sharing sequence
homology and the ability to bind lipid droplets, they differ in
their sizes, tissue expression profiles, transcriptional regulation
and affinities for lipid droplets. Depending on their expression
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FIGURE 3 | Characterization of anti-PLIN1 autoantibodies in patients with AGL. (A) Equal amounts of human adipose tissue were electrophoresed under reducing
(2BME +) and nonreducing (2BME –) conditions. Membrane was incubated with either reactive serum samples from two patients with AGL as source of antibodies or
a polyclonal anti-PLIN1 IgG (#AF6615) and detected with appropriate secondary antibodies. (B) Results of ELISA analyses demonstrating that IgG from three patients
with AGL (ALG1, AGL2, and ALG3) binds to recombinant human PLIN1. Neither serum from healthy donors (n = 20, NHS), nor from patients with acquired partial
lipodystrophy (n = 8, APL), localized lipoatrophy due to intradermic insulin injections (n = 11, I-LA), and systemic lupus erythematosus (n = 10, SLE) reacted against
recombinant human PLIN1 on ELISA assay. Samples were run in duplicates. Each point represents the mean value of optical density (O.D.) for each sample. (C) White
adipose tissue extracts were blotted with serum samples from three anti-PLIN1-positive patients (AGL1 through AGL3), followed by detection with antibodies specific
for each human IgG subclass (1 through 4), and peroxidase conjugated anti-subclass-specific IgG antibodies. (D) Blotted human adipose tissue proteins were
revealed using serum from a patient with anti-PLIN1 autoantibodies either pre-incubated (right) or not (left) with recombinant human PLIN1. PLIN1 detection is blocked
by the recombinant protein, thus demonstrating specificity.
patterns, PLINs can be classified into two groups: PLINs
expressed in a tissue-restricted manner (PLIN1, PLIN4 and
PLIN5) and those with ubiquitous expression (PLIN2 and
PLIN3). Besides, from amechanistic perspective, some PLINs are
constitutively bound to lipid droplets (PLIN1 and PLIN2) while
others exhibit exchangeable lipid droplet binding (PLIN3, PLIN4
and PLIN5) (18, 19). PLIN2, PLIN3, and PLIN5 differ from
PLIN1 in their C-terminal sequences, which are considerably
shorter (20).
PLIN1 is the founding and best characterized member of
the perilipin family, with six phosphorylation sites (Ser-81,
Ser-223, Ser-277, Ser-434, Ser-492, and Ser-517) (17, 21).
Under basal (e.g., fed or insulin-stimulated) conditions, PLIN1
is unphosphorylated, and the two major lipolytic enzymes,
adipose triacylglycerol lipase (ATGL) and hormone-sensitive
lipase (HSL), are cytosolic and do not interact with lipid
droplet-associated proteins. Moreover, via its C-terminal
portion, unphosphorylated PLIN1 hijacks the ATGL activator
comparative gene identification-58 (CGI-58), and lipolysis is
suppressed (21). PLIN1 is available for rapid phosphorylation
upon β-adrenergic stimulation. C-terminal phosphorylation
of PLIN1 disrupts the interaction with CGI-58, allowing it
to recruit, mobilize, and activate ATGL, which catalyzes the
initial step of lipolysis. N-terminal phosphorylation of PLIN1
is essential for HSL recruitment on the lipid droplet surface
(17, 19, 21). PLIN1 is expressed in adipocytes where it remains
bound to the cytosolic lipid droplet and participates in the
regulation of triacylglycerol storage and breakdown (17). Under
basal conditions, PLIN1 restricts the access of cytosolic lipases
to the neutral lipid core, thus promoting triacylglycerol storage,
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FIGURE 4 | Colocalization of PLIN1 and anti-PLIN1 autoantibodies from patients with acquired generalized lipodystrophy. Confocal microscopic analysis of human
preadipocytes revealed colocalization of PLIN1 and anti-PLIN1 IgG from AGL1 on the lipid droplet surface. However, no colocalization was observed when using
serum from AGL4 and AGL5 (negative for anti-PLIN1 autoantibodies). DNA was stained with 4′,6-diamidino-2-phenylindole (DAPI, blue); IgG binding was detected
using FITC-conjugated rabbit anti-human IgG (green); PLIN1 was detected with biotin-labeled rabbit IgG followed by Texas Red-labeled streptavidin (red). Scale bars
correspond to 18µm.
whereas upon β-adrenergic or adrenocorticotropic hormone
stimulation, HSL is the major enzyme responsible of diglyceride
hydrolysis (21). This is evidenced by the phenotype of PLIN1 null
mice, which have a 65–70% reduction of adipose triacylglycerol
storage compared with wild-type animals and are resistant to
diet-induced obesity. Adipocytes isolated from perilipin null
mice have a higher rate of basal lipolysis, which is consistent with
the role for PLIN1 in protecting the core of the lipid droplet from
the action of lipases. Strikingly, PLIN1 null mice also exhibit a
reduced rate stimulated lipolysis due to the lack of a functional
N-terminal PLIN1 domain responsible for HSL recruitment and
diglyceride breakdown in the presence of the appropriate stimuli
(22).
The consequences of defective lipid storage are dramatically
apparent in rare human monogenic disorders of fat storage
(lipodystrophies), in which the inability to store dietary
lipids in the lipid droplets of specialized white adipose cells
causes increased lipid deposits (ectopic fat) in nonadipose
tissues, including skeletal and heart muscle, liver, and pancreas
(17). FPLD4 is caused by autosomal dominant C-terminal
mutations in PLIN1. When expressed in preadipocytes, human
mutant PLIN1 proteins are associated with smaller lipid
droplets, reduced triacylglycerol accumulation, and increased
basal lipolysis. These in vitro results were concordant with
FIGURE 5 | Strategy used for the characterization of the domains recognized
by anti-PLIN1 autoantibodies. Results of a western blot screening performed
on human adipose tissue extracts, under reducing (2BME +) or non-reducing
(2BME –) conditions, incubated with serum sample from one patient with
acquired generalized lipodystrophy (AGL1), or two polyclonal anti-PLIN1
antibodies directed against different regions of the protein. PαPLIN1
corresponds to antibody #AF6615 from R&D. D418 corresponds to the results
obtained using a rabbit polyclonal anti-PLIN1 antibody targeting the C-terminal
domain. Arrows indicate unspecific binding by the secondary antibody.
morphometric analyses of adipose tissue in patients with FPLD4,
showing smaller adipocytes than those of unaffected individuals
(9, 10, 23). Interestingly, reduced expression of mutant PLIN1
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FIGURE 6 | Mouse PLIN1 detection using serum from patients with AGL. (A) Tissue extracts were blotted with sera (1:100 dilutions) from patients with AGL known to
be reactive (AGL1 and AGL2) or non-reactive (AGL5) with human PLIN1. Reactive sera from patients with AGL detect the two major isoforms of mouse PLIN1 (called
PLINA and PLINB). As a positive control, the extract was blotted with a rabbit polyclonal anti-PLIN1 antibody. (B) Confocal microscopic analysis of mouse
preadipocytes revealed colocalization of PLIN1 and IgG from patient AGL3 on the lipid droplet surface (merged image, in yellow). However, no colocalization was
observed when using serum from one healthy donor (NHS). DNA was stained with 4′,6-diamidino-2-phenylindole (DAPI, blue); IgG binding was detected using
FITC-conjugated rabbit anti-human IgG (green); PLIN1 was detected with biotin-labeled rabbit IgG followed by Texas Red-labeled streptavidin (red). Scale bars
correspond to 18µm.
in FLPD4 patients induces overexpression of PLIN2, which can
in no way restore lipolysis regulation and normal phenotype
due to the lack of a full C-terminal region in these PLIN
homolog (10).
In our study, anti-PLIN1 autoantibodies detected in patients
with AGL were found to increase basal lipolysis in cultured
preadipocytes (Figure 7). Previous reports involving animal
models have shown that fat loss can be caused by antibodies
against adipose tissue (24–29). As demonstrated by Cheng et al.
administration of a monoclonal anti-adipocyte antibody causes
a reduction in body fat mass by suppressing subcutaneous
adipose tissue development, reducing triglyceride biosynthesis,
and promoting triglyceride lipolysis in adipose tissue (24).
Although we did not investigate the in vivo mechanism of
action of the anti-PLIN1 antibodies in AGL, it is conceivable
that they might act by blocking key domains with a role in
the attenuation of basal lipolysis. In order to map the epitope/s
targeted by the anti-PLIN1 autoantibodies, we performed
western blot assays with a different polyclonal anti-PLIN1
antibody specifically binding to the protein’s C-terminal domain
(D418) and found that it exclusively recognized the 60 and 55
kDa, but not the 37 kDa bands. Considering that the commercial
polyclonal antibody #AF6615 and anti-PLIN1 autoantibodies
equally recognize the 60, 55, and 37 kDa bands when blotted
against healthy donors’ adipose tissue extracts, this result is
consistent with the 37 kDa band being a C-terminal truncated
splicing variant of PLIN1 (Figure 5). The existence of a 37.5
kDa mouse splicing variant lacking C-terminal amino acids
downstream to 422 (Uniprot Q8CGN5-3), also supports the 37
kDa band observed by us (Figure 1) representing the human
splicing variant homologous to that short mouse isoform.
However, in the absence of further studies, we cannot discard
that such band represents a different autoantigen not related
to PLIN1 and further research is being carried out to clarify
this point. All considered, the most likely explanation is that
the immune response inducing the appearance of anti-PLIN1
autoantibodies in patients with AGL was of polyclonal nature,
thus targeting several epitopes throughout the protein. For
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FIGURE 7 | Functional effects of anti-PLIN1 autoantibodies on lipolysis.
Preadipocytes (3T3-L1) were incubated overnight with [3H]palmitic acid at
37◦C. (A) Results of the radiometric assessment of basal and stimulated
lipolysis after 1, 2, and 3 h in preadipocytes treated with 300 micrograms of
IgG purified from one patient with acquired generalized lipodystrophy (AGL3)
with anti-PLIN1 autoantibodies and a healthy donor (NHS). Cells treated with
IgG from patient AGL3 showed a significant increase in [3H]palmitic acid
release under basal (**P < 0.01 at 2 h; ***P < 0.001 at 1 and 3 h) compared
with cells treated with NHS IgG. Data represent mean ± SD, for triplicates of
two independents experiments for each sample. Statistical significance was
assessed with two-way ANOVA assay. (B) Radiolabeled palmitic acid release
under basal conditions in preadipocytes treated with 300 micrograms of IgG
purified from patient’s AGL1, AGL2, AGL4 and AGL5 sera and a NHS. A
commercial human PLIN1 Antigen Affinity-purified Polyclonal Antibody (10 µg
per well) was used as positive control for blocking lipolysis regulation. Under
these conditions, IgG purified from patients AGL1 and AGL2 induced a
significant increase of basal lipolysis (**P < 0.01), comparable to that induced
by a polyclonal anti-PLIN1 antibody (#AF6615 from R&D). Data represent
mean ± SD, for triplicates of two independents experiments for each sample.
Statistical significance was assessed with one-way ANOVA assay comparing
the mean of each column with the mean of a control column (IgG NHS). n.s.,
not significant.
example, binding of the autoantibody to the unphosphorylated
C-terminal region could prevent the binding of CGI-58,
thus allowing unrestrained lipolysis by ATGL during basal
conditions, as demonstrated in perilipin null mice (22) and
in patients with FPLD4 (9, 10, 23). However, the phenotype
of fat mass loss in patients with AGL diverges from that
characteristic of patients with FPLD4. These differences might
be due to anti-PLIN1 autoantibodies blocking additional sites
with relevant functions for PLIN1, for example the portion
spanning amino acids 291–319, which is required for the
interaction with CIDEC (30). Considering that stimulated
lipolysis is determined by the N-terminal phosphorylation state
and that the former is not affected by the autoantibody, the
most likely interpretation of our results is that anti-PLIN1
autoantibodies bind to and block the central and C-terminal
regions of the protein. To better support this hypothesis, further
experiments are scheduled for the production of recombinant
PLIN1 fragments in order to map the epitope/s recognized
by anti-PLIN1 autoantibodies using immunochemical tools.
Moreover, the availability of PLIN1 peptides will allow mice
immunization and the generation of anti-PLIN1 antibodies
specifically targeting amino- or carboxi-terminal domains.
Finally, functional assessment of these autoantibodies on
basal lipolysis could be eventually carried out using cultured
preadipocytes.
In our cohort of five patients with AGL, three presenting
the autoimmune variety of the disease (Table 1) had antibodies
against PLIN1, whereas idiopathic cases were negative. The
observed frequency of autoantibodies is most probably biased
because of the low proportion of idiopathic cases and the
absence of panniculitis-associated phenotypes in the cohort.
Indeed, in our view, antibodies directed against adipose tissue
should also be investigated in panniculitis-associated AGL cases,
since this presentation of the disease is typically accompanied
by autoimmune diseases (although at lower frequencies than
autoimmune AGL).
We describe here the finding of autoantibodies against
PLIN1, one of the most abundant proteins on the lipid droplet
surface of mature white adipocytes, in the serum of three
patients with the autoimmune variety of AGL. As a result, anti-
PLIN1 IgG autoantibodies from patients were able to induce
a significant elevation of basal lipolysis in cultured mouse
3T3-L1 preadipocytes. Our data provide strong support for
the conclusion that anti-PLIN1 autoantibodies are implicated
in the pathogenesis of the generalized lipodystrophy in these
patients. Despite the identification of anti-PLIN1 antibodies,
we do not discard that autoimmune AGL patients may target
other, additional autoantigens. As shown in other autoimmune
pathologies, multiple antigens can be involved in a single disease
process, whether as markers or casual factors (31, 32). Further
research, probably with a more throughput approach, is needed
to identify other possible antigens and their involvement in AGL.
The finding of anti-PLIN1 autoantibodies in patients with AGL
sheds light on the pathophysiology of the disease, provides a
target for its difficult diagnosis and opens the possibility for novel
therapeutic strategies.
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